Post hoc analyses of studies involving direct factor Xa inhibitors in AF patients (ROCKET AF, ARISTOTLE, ENGAGE AF-TIMI trial) and observational data indicate that DOAC are not only safer in terms of bleeding but also at least as effective as VKA in patients with active cancer [5,18]. The gene discussed is F10; the disease is atrial fibrillation.